Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hologic, Inc. (HOLX) CEO Steve MacMillan’s Take on Carl Icahn

Hologic, Inc. (NASDAQ:HOLX), a medical device and diagnostics manufacturer, saw an unprecedented increase in investors’ interest, after the billionaire activist investor, Carl Icahn, purchased a 12.5% stake in the company last November. Icahn also asked Hologic, Inc. (NASDAQ:HOLX)’s board to include two of his nominees, expanding the size of the board.

ICAHN CAPITAL Carl Icahn

Steve MacMillan, President and CEO of Hologic, Inc. (NASDAQ:HOLX) has discussed on CNBC about Icahn’s stake in the company and his style of functioning.’

“You know what; he [Carl Icahn] has actually been very good. I would say he has a very simple model, which is create shareholders’ value, which frankly is what our other large shareholders looked at and I think a lot of people looked at this company and thought it has tremendous assets, but was being effectively undervalued and I think we have been totally focused. I have done here what I have done my whole career, which is build great teams, raise the bar on expectations, focus on innovation and then the shareholder value creation starts to come […],”  MacMillan said.

Macmillan revealed that Icahn focuses little on things like technology and other business aspects, instead his main focus is on whether the Company that he has stakes in has the right management team in place. He also shared that when Icahn saw a new technology he asked Macmillan if he can make it better.

“I think it’s the sixth sense and I think it’s a belief in at the macro level are you focusing on the right things, but clearly not a micromanager and not into our shorts at all,” MacMillan added.

 According to our records, Carl Icahn’s Icahn Capital owns 34.15 million shares of Hologic, Inc. (NASDAQ:HOLX) as of the end of the first quarter of 2014.

Disclosure: None

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!